Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Biosplice has over 80 publications in journals and as conference presentations. The company is headquartered in San Diego, California.
The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). The company is also on the preclinical stages of developing an anti-Alzheimer's disease drug.
- Media news
- Corp news
- Combo news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to Biosplice Therapeutics
CIO Leadership: Opportunities for Female Tech Leaders to Foster ...
CIOs and business technology executives at this event will also discuss how men...https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html
Week in review: Everest announces 2 in-licensings with total value ...
Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. Cue Health filed for a $180 mln IPO ...https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion
Biosplice Licenses Development and Commercialization Rights for ...
SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company...https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo